Vanda Pharmaceuticals | VNDA - Sales Revenues


Vanda Pharmaceuticals reported $198.77M in Sales Revenues for its fiscal quarter ending in December of 2024.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
J&J USD 24.1B 500M Mar/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Merck USD 16.4B 880M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 678M 342M Dec/2025
Novartis USD 13.86B 498M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.3B 1.13B Dec/2025
Takeda JPY 1.19T 80B Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Veracyte USD 140.6M 8.7M Dec/2025